Machine Learning in Pharmaceutical Industry Market

Global Machine Learning in Pharmaceutical Industry Market Size, Share & Industry Trends Analysis Report By Component (Solution and Services), By Deployment Mode (Cloud and On-premise), By Organization size, By Regional Outlook and Forecast, 2023 - 2029

Report Id: KBV-15086 Publication Date: April-2023 Number of Pages: 200
Special Offering:
Industry Insights | Market Trends
Highest number of Tables | 24/7 Analyst Support

Market Report Description

The Global Machine Learning in Pharmaceutical Industry Market size is expected to reach $11.4 billion by 2029, rising at a market growth of 34.4% CAGR during the forecast period.

The purpose of machine learning in the pharmaceutical industry is to advance medical knowledge, not to replace a doctor. A physician's whole body of knowledge, which includes everything they acquired in medical school and during their training, in addition to their experience treating patients, is scaled to unprecedented levels by artificial intelligence algorithms.

Machine Learning in Pharmaceutical Industry Market Size - Global Opportunities and Trends Analysis Report 2019-2029

The ability to obtain and process the vast quantity of data available to doctors—information on new treatments, disease symptoms, drug interactions, and how different patients treated in the same way can have different outcomes—is quickly emerging as a crucial talent. And machine learning makes it possible for them to make inferences from that data and put them into action. For instance, machine learning systems may quickly identify a rare ailment, browse the available treatments, and prescribe by compiling data from many patient visits and thousands of doctors. As a result, time is saved, which leads to increased effectiveness and decreased expenses.

Machine learning can also prevent recidivism by helping to follow up on instances and providing extra recommendations. AI is integrated with electronic medical records. When a doctor uses them irregularly, a pop-up appears explaining how particular genetic features can affect the patient's condition or how a new medication could enhance their health. A doctor can better understand the illness and recommend the best course of treatment by clicking the pop-up.

Not only are these electronic records saving time and space, but they are also actively assisting doctors in formulating better treatment recommendations and educating them on the details in front of them. Some countries with a high lung cancer patient population are beginning to deploy AI programs to help doctors better diagnose lung cancer patients by analyzing X-rays and CT scans and spotting suspicious nodules and lesions.

COVID-19 Impact Analysis

Machine learning in pharmaceutical industry market, was positively affected by the COVID-19. The utilization of machine learning has been instrumental in the advancement of treatments and vaccines within the pharmaceutical sector. In addition, prospective COVID-19 drug candidates have been found due to the use of ML. Machine learning algorithms can sift through huge amounts of data from genetic databases and clinical trials to identify compounds potentially effective against the virus. This has contributed to speeding the drug discovery process, which ordinarily takes years, and has led to the quick development of many novel COVID-19 medications.

Market Growth Factors

Predicting epidemic beforehand

Businesses are utilizing AI and machine learning to provide users with the precise place and date of the upcoming outbreak, like a dengue outbreak, a few months in advance. This program also suggests anti-dengue measures a few hundred meters around the contaminated area. Thus, using machine learning, researchers can foresee the timing and location of impending epidemics, alert the relevant authorities, and inform the general public about it. This capability has the potential to save a significant number of lives, which is expected to increase machine learning's adoption and open up new growth opportunities for the market.

Increasing use of technologies in the medical industry

Patient treatment is made simpler and more productive using electronic summaries instead of paper. Future advances in genomes (and the enormous genomics of the symbiotic bacteria) and tailored therapy will greatly increase the amount of information available. As more patient data is gathered, more insights will become accessible. The increased use of machine learning in the pharmaceutical industry is anticipated to drive market growth due to its various benefits, including cost reduction, management, and the collection of massive patient data for future reference.

Market Restraining Factors

Inconsistency of data

Harmonizing all the data and performing analytics over the data set is challenging when many data sources are used. Companies that choose a point solution or do not have a robust data analytics system must manually compile analytics reports and insights. Such a procedure takes a lot of time and might not produce any insights with practical business relevance. Thus, the issues associated with data are expected to hinder machine learning in pharmaceutical industry market's expansion.

Component Outlook

Based on Component, the machine learning in pharmaceutical industry market is segmented into solution and services. The solution segment held the highest revenue share in the machine learning in pharmaceutical industry market in 2022. This is due to the fact that the pharmaceutical industry produces enormous amounts of data when creating and discovering new medicines. ML algorithms can process and analyze this data to find patterns, connections, and insights that can guide drug development decisions. The demand for machine learning solutions in the pharmaceutical industry is further increased by the desire for quicker and more affordable drug research and development processes.

Organization size Outlook

On the basis Organization size, the machine learning in pharmaceutical industry market is divided into SMEs and large enterprises. The large enterprises segment witnessed the largest revenue share in the machine learning in pharmaceutical industry market in 2022. This is because large pharmaceutical corporations can use machine learning technology to evaluate enormous volumes of data from numerous sources, including electronic health records, clinical trials, and genetic information, to find prospective drug targets, forecast patient outcomes, and improve clinical trial design.

Machine Learning in Pharmaceutical Industry Market Share and Industry Analysis Report 2022

Deployment Mode Outlook

By deployment mode, the machine learning in pharmaceutical industry market is classified into cloud and on-premise. The on-premise segment garnered a prominent revenue share in the machine learning in pharmaceutical industry market in 2022. This is because on-premise services can save more capital than cloud services, as the use and distribution of data can be CPU/GPU intensive, making it expensive to maintain an ML process in a public cloud on a pay-as-you-go basis. The data set might need to be bigger to migrate to the public cloud, adding complexity and cost.

Machine Learning in Pharmaceutical Industry Market Report Coverage
Report Attribute Details
Market size value in 2022 USD 1.5 Billion
Market size forecast in 2029 USD 11.4 Billion
Base Year 2022
Historical Period 2019 to 2021
Forecast Period 2023 to 2029
Revenue Growth Rate CAGR of 34.4% from 2023 to 2029
Number of Pages 200
Number of Table 322
Report coverage Market Trends, Revenue Estimation and Forecast, Segmentation Analysis, Regional and Country Breakdown, Competitive Landscape, Companies Strategic Developments, Company Profiling
Segments covered Offering, Organization size, Deployment Mode, Region
Country scope US, Canada, Mexico, Germany, UK, France, Russia, Spain, Italy, China, Japan, India, South Korea, Singapore, Malaysia, Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria
Growth Drivers
  • Predicting epidemic beforehand
  • Increasing use of technologies in the medical industry
  • Inconsistency of data

Regional Outlook

Region-wise, the machine learning in pharmaceutical industry market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America region led the machine learning in pharmaceutical industry market by generating the maximum revenue share in 2022. With a strong emphasis on R&D, the pharmaceutical business in North America makes a considerable contribution to the market. The market has adopted machine learning in recent years to spur innovation, boost productivity, and quicken medication discovery and development.

Free Valuable Insights: Global Machine Learning in Pharmaceutical Industry Market size to reach USD 11.4 Billion by 2029

KBV Cardinal Matrix - Machine Learning in Pharmaceutical Industry Market Competition Analysis

 Machine Learning in Pharmaceutical Industry Market - Competitive Landscape and Trends by Forecast 2029

The major strategies followed by the market participants are Partnerships. Based on the Analysis presented in the Cardinal matrix; Microsoft Corporation and Google LLC are the forerunners in the Machine Learning in Pharmaceutical Industry Market. Companies such as NVIDIA Corporation, IBM Corporation and Cyclica, Inc. are some of the key innovators in Machine Learning in Pharmaceutical Industry Market.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Google LLC (Alphabet, Inc.), NVIDIA Corporation, IBM Corporation, Microsoft Corporation, Cyclica, Inc., BioSymetrics Inc., Cloud Pharmaceuticals, Inc., Deep Genomics Incorporated and Atomwise, Inc.

Strategies deployed in Machine Learning in Pharmaceutical Industry Market

» Partnerships, Collaborations and Agreements:

  • Mar-2023: NVIDIA collaborated with AWS, a US-based provider of the cloud-based web platform. The collaboration focuses on developing infrastructure for training large ML models and developing generative AI applications. This collaboration supports customers to make the best use of accelerated computing and generative AI to further explore opportunities.
  • Oct-2022: BioSymetrics partnered with Deerfield Management, a US-based healthcare investment firm. The partnership focuses on advancing the development of therapeutics. Additionally, as per the agreement, both companies would work on identifying therapeutic targets through BioSymetrics' database and platform.
  • Jun-2022: Cyclica partnered with Oncocross, a South Korea-based developer of cancer drugs. The partnership includes the discovery and designing of treatments intended for myelofibrosis.
  • Feb-2022: BioSymetrics came into partnership with Sema4, a US-based health intelligence company. The partnership focuses on drug discovery based on data to accelerate precision medicine. The companies through this partnership aim to deliver an innovative and differentiated method for drug discovery. Further, Sema4's multi-omic data insights and access enhance BioSymetrics' capabilities to discover treatments intended for people with different diseases.
  • Feb-2022: Microsoft entered into a partnership with Tata Consultancy Services, an Indian company focusing on providing information technology services and consulting. Under the partnership, Tata Consultancy Services leveraged its software, TCS Intelligent Urban Exchange (IUX) and TCS Customer Intelligence & Insights (CI&I), to enable businesses in providing hyper-personalized customer experiences. CI&I and IUX are supported by artificial intelligence (AI), and machine learning, and assist in real-time data analytics. The CI&I software empowered retailers, banks, insurers, and other businesses to gather insights, predictions, and recommended actions in real time to enhance the satisfaction of customers.
  • Aug-2021: IBM Corporation came into partnership with Cloudera, an American software company providing enterprise data management systems. Through this partnership, both companies would help enterprises with their AI and Data needs. Additionally, this would allow IBM to let Cloudera reside under the IBM Data Fabric which would enable business access to the right data at a better cost, regardless of the data's storage location.
  • Sep-2021: Deep Genomics announced a partnership with Mila, an AI institute based in Canada. The partnership agreement allows Deep Genomics to join the AI institute's community and make use of the institute's recruitment activities.
  • Mar-2021: IBM partnered with Cleveland Clinic, a US-based nonprofit medical center. The partnership involves establishing a discovery accelerator, a joint Cleveland clinic, and an IBM center, with the aim to accelerate the speed of discovery in multiple areas including, single-cell transcriptomics, clinical applications, etc. by using high-performance computing on AI, quantum computing technologies, and hybrid cloud.

» Product Launches and Product Expansions:

  • Nov-2022: NVIDIA joined hands with Microsoft, a US-based tech giant. The collaboration focuses on developing powerful cloud AI computers. The AI supercomputer would be developed by leveraging, Microsoft's Azure supercomputing infrastructure and NVIDIA's GPUs. Further, this collaboration provides advanced AI infrastructure and software to researchers and companies.
  • May-2021: Google released Vertex AI, a novel managed machine learning platform that enables developers to more easily deploy and maintain their AI models. Engineers can use Vertex AI to manage video, image, text, and tabular datasets, and develop machine learning pipelines to train and analyze models utilizing Google Cloud algorithms or custom training code. After that, the engineers can install models for online or batch use cases all on scalable managed infrastructure.
  • Mar-2021: Microsoft released updates to Azure Arc, its service that brought Azure products and management to multiple clouds, edge devices, and data centers with auditing, compliance, and role-based access. Microsoft also made Azure Arc-enabled Kubernetes available. Azure Arc-enabled Machine Learning and Azure Arc-enabled Kubernetes are developed to aid companies to find a balance between enjoying the advantages of the cloud and maintaining apps and maintaining apps and workloads on-premises for regulatory and operational reasons. The new services enable companies to implement Kubernetes clusters and create machine learning models where data lives, as well as handle applications and models from a single dashboard.

» Mergers and Acquisitions:

  • Jul-2021: IBM entered into an agreement to acquire Bluetab Solutions Group, an enterprise software, and technical services company. Through this acquisition, Bluetab would become a strategic part of IBM's data services consulting practice to improve its hybrid cloud and AI strategy.

Scope of the Study

Market Segments Covered in the Report:

By Component

  • Solution
  • Services

By Deployment Mode

  • Cloud
  • On premise

By Organization size

  • Large Enterprises
  • SMEs

By Geography

  • North America
    • US
    • Canada
    • Mexico
    • Rest of North America
  • Europe
    • Germany
    • UK
    • France
    • Russia
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Singapore
    • Malaysia
    • Rest of Asia Pacific
    • Brazil
    • Argentina
    • UAE
    • Saudi Arabia
    • South Africa
    • Nigeria
    • Rest of LAMEA

Key Market Players

List of Companies Profiled in the Report:

  • Google LLC (Alphabet, Inc.)
  • NVIDIA Corporation
  • IBM Corporation
  • Microsoft Corporation
  • Cyclica, Inc.
  • BioSymetrics Inc.
  • Cloud Pharmaceuticals, Inc.
  • Deep Genomics Incorporated
  • Atomwise, Inc.
Need a report that reflects how COVID-19 has impacted this market and its growth? Download Free Sample Now

Frequently Asked Questions About This Report

The Market size is projected to reach USD 11.4 billion by 2029.

Predicting epidemic beforehand are driving the Market in coming years, however, Inconsistency of data restraints the growth of the Market.

AGoogle LLC (Alphabet, Inc.), NVIDIA Corporation, IBM Corporation, Microsoft Corporation, Cyclica, Inc., BioSymetrics Inc., Cloud Pharmaceuticals, Inc., Deep Genomics Incorporated and Atomwise, Inc.

The expected CAGR of this Market is 34.4% from 2023 to 2029.

The Cloud segment acquired maximum revenue share in the Global Machine Learning in Pharmaceutical Industry Market by Deployment Mode in 2022 thereby, achieving a market value of $7.7 billion by 2029.

The North America market dominated the Market by Region in 2022, and would continue to be a dominant market till 2029; thereby, achieving a market value of $4.5 billion by 2029.



Call: +1(646) 600-5072


  • Buy Sections of This Report
  • Buy Country Level Reports
  • Request for Historical Data
  • Discounts Available for Start-Ups & Universities

Unique Offerings Unique Offerings

  • Exhaustive coverage
  • The highest number of Market tables and figures
  • Subscription-based model available
  • Guaranteed best price
  • Support with 10% customization free after sale

Trusted by over
5000+ clients

Our team of dedicated experts can provide you with attractive expansion opportunities for your business.

Client Logo